CSL Limited Annual Report 2022/23 28 Over the last 12 months CSL has taken steps to create an integrated and simpler organisation with focus on its three businesses, CSL Behring (which includes CSL Plasma), CSL Vifor and CSL Seqirus. These businesses are supported by CSL’s global enabling functions, global R&D organisation and global centres of excellence. The ongoing integration of CSL Vifor, combined with continued investment in CSL’s people and in digital transformation provides a good foundation for CSL to continue executing its 2030 Strategy. In the medium term CSL Behring expects to continue to grow through fulfilling unmet demand for products driven by increased plasma collections, developing differentiated plasma-derived and recombinant products, expanding markets and indications for those products and developing cell and gene therapies. CSL Seqirus expects growth with its portfolio of differentiated products, including its adjuvanted quadrivalent influenza vaccine in the 65 years and over market. CSL Vifor’s growth is largely focused on unlocking the value and growth within this newly acquired business by bringing together CSL’s research and development capabilities into the one R&D organisation. We are also combining nephrology and transplant therapeutic areas and have a number of patient blood management initiatives underway that cross between CSL Vifor and CSL Behring. In the longer term CSL expects sustained demand for immunoglobulins driven by significant need in Primary Immune Deficiency and Secondary Immune Deficiency. In the haematology therapeutic area, HEMGENIX®, CSL’s one-time gene therapy for the treatment of adults with haemophilia B, provides another option to patients, complementing IDELVION®, a long-acting recombinant factor IX product. CSL also expects demand for vaccines to continue and be supported with its new recombinant protein and next-generation mRNA technologies. There remains significant unmet need for products to address anaemia, and CSL Vifor will continue to play an important role in this therapeutic area. Further information about CSL’s product pipeline is set out on pages 10 and 11 and details of new products being brought to market are set out on pages 14 and 15. Driven by its promise to patients, and guided by its Values in decision making, CSL remains committed to delivering innovative medicines that save lives, protect public health and help people with life-threatening medical conditions to live full lives. More information in relation to CSL’s outlook is provided in the Chair and CEOmessages, and further information on the factors that could affect this section is provided in CSL’s Material Risks on page 26. 5 CSL’s Future Prospects
RkJQdWJsaXNoZXIy MjE2NDg3